Leadless Pacemakers Market Size and Trends

The Global Leadless Pacemakers Market is estimated to be valued at USD 804.1 Mn in 2025 and is expected to reach USD 1,965.2 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 13.6% from 2025 to 2032.

Key Takeaways of the Leadless Pacemakers Market:

By product type, the micra transcatheter pacing system segment is expected to contribute the highest share of the market with 45.1% in 2025.
By type, the single chamber segment is expected to contribute the highest share of the market with 51.2% in 2025.
By end user, the hospitals segment is expected to contribute the highest share of the market with 36.2% in 2025.
North America is expected to top the global market with 32.3% share, followed by Asia Pacific with 25.4% share in 2025.

Market Overview:

The significant growth can be attributed to the increasing prevalence of cardiovascular diseases and the rising geriatric population globally. The emerging technologies and innovations in leadless pacemakers are likely to provide opportunities for manufacturers. Miniaturization and battery longevity are some developments expected to positively impact the market. However, stringent regulatory approvals and high cost of these devices may hamper market growth to some extent during the analysis period.

Leadless Pacemakers Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In November 2024, launched the AVEIR VR (Ventricular Rate) leadless pacemaker in India, following approval by the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (FDA). This advanced device, designed for patients with slow heart rhythms, is implanted directly into the heart’s right ventricle via a minimally invasive catheter-based procedure, eliminating the need for chest incisions or leads.
In May 2024, Medtronic, a pioneer in healthcare technology, advanced pacemaker innovation with the U.S. FDA approval of its Micra AV2 and Micra VR2. These miniaturized, leadless devices offer extended battery life and easier programming, broadening access to this therapy.
In January 2024, Medtronic Plc., a healthcare technology company, received the Conformité Européenne (CE) Mark for its Micra AV2 and Micra VR2, the next-generation miniature leadless pacemakers, following U.S. FDA approval in 2023. These devices, the smallest pacemakers globally, offer 40% longer battery life (16–17 years) and easier programming, with over 80% of patients needing only one device for life.

Top Strategies Followed by Global Leadless Pacemakers Market Players

Established Players: Leading companies prioritize extensive research and development to innovate high-performance products
- For instance, Abbott's Aveir Leadless Pacemaker system, approved by the U.S. FDA in April 2022, features increased battery longevity and retrievability, reflecting significant R&D efforts
Collaborations with major industry players enhance market presence. In April 2021, Medtronic partnered with a cybersecurity startup, Sternum, to protect its pacemakers from potential hacking, demonstrating the importance of alliances in ensuring device security.
Mid-Level Players: Mid-level companies focus on delivering quality, budget-friendly products targeting price-sensitive consumers. While specific instances are limited, the general trend involves optimizing manufacturing processes to reduce costs and offer competitive pricing.
- Partnerships aimed at enhancing technology and market presence are common. For example, in December 2021, Boston Scientific initiated a trial to evaluate the industry's first modular CRM system, combining the EMBLEM S-ICD and the EMPOWER Leadless Pacemaker, indicating collaborative efforts in product development.
Small players typically focus on niche markets by offering unique features or innovative products. By addressing specialized patient needs, these companies can differentiate themselves in the market.
- Embracing cutting-edge technologies is crucial for competitiveness. In January 2024, Sweden-based startup, Acorai, developed a non-invasive heart pressure monitoring tool, combining proprietary sensing hardware and machine learning, showcasing technological innovation in cardiac care.

Emerging Startups - Leadless Pacemakers Industry Ecosystem

Innovative Technologies: Startups are developing technologies like Cardiomems' wireless sensor for continuous blood pressure monitoring and cardiac output measurements. This has potential to transform remote patient monitoring and disease management. U.S.-based Prefix aims to enhance pacing capabilities with its AI-powered pacemaker optimized through deep neural networks.
Sustainable Solutions: Some startups focus on sustainability. Denmark's CorTronix develops fully biodegradable pacemakers using environment-friendly materials that safely degrade in the body over time. Their disposable, single-use devices aim to reduce electronic waste. Croatia's Imeka produces miniature pacemakers with recycled batteries and minimal packaging to lower environmental impact.
Market Contribution: Startups address niche needs. Israel's LEADLESS aims to develop the world's first leadless defibrillator for atrial fibrillation, targeting an underserved market. Partnerships between startups and established companies or research institutions drive technological and sustainable innovation, facilitating the development and commercialization of advanced leadless pacemaker technologies.